Finance

Lists
DRUG:CNSX
Bright Minds Biosciences Inc
CA$108.16
-1.14%
(-1.25) 1D
Aug 21, 4:00:00 PM GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for DRUG...
Open
CA$107.75
High
CA$108.27
Low
CA$106.78
Mkt. cap
1.07B
Avg. vol.
758.00
Volume
801.00
52-wk high
CA$170.00
52-wk low
CA$53.99
EPS
-CA$3.40
No. of employees
26
Open
CA$107.75
High
CA$108.27
Low
CA$106.78
Mkt. cap
1.07B
Avg. vol.
758.00
Volume
801.00
52-wk high
CA$170.00
52-wk low
CA$53.99
EPS
-CA$3.40
No. of employees
26
Profile
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HTâ‚‚ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
About Bright Minds Biosciences Inc
CEO-
Employees26
Founded2017
Headquarters-
SectorBiotechnology
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.78M
5.66M
13.05M
9.25M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
749.11K
1.08M
2.23M
2.15M
Operating expense
5.79M
6.74M
15.28M
11.41M
Total operating expenses
5.79M
6.74M
15.28M
11.41M
Operating income
-5.79M
-6.74M
-15.28M
-11.41M
Other non operating income
-123.93K
-154.22K
-42.48K
-27.84K
EBT including unusual items
-4.09M
-7.57M
-10.46M
-2.40M
EBT excluding unusual items
-4.09M
-7.57M
-10.46M
-2.40M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
257.87K
-
-
-
Net income
-4.09M
-7.57M
-10.46M
-2.40M
Net profit margin
-
-
-
-
Earnings per share
-0.58
-0.97
-1.09
-0.24
Interest and investment income
529.54K
818.26K
2.69M
2.79M
Interest expense
-7.30K
-6.58K
-
-
Net interest expenses
522.24K
811.69K
2.69M
2.79M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps